You just read:

ViaCyte Substantially Expands Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

News provided by

ViaCyte, Inc.

Apr 17, 2018, 09:00 ET